Hijazi Z, et al. - A RE-LY trial analysis was performed in order to assess the efficacy and safety of dabigatran compared with warfarin in patients with atrial fibrillation (AF) in relation to renal function over time. As per observations, worsening renal function (WRF) was associated with a higher risk of death and major bleeding in AF. Similar efficacy and safety profile of dabigatran compared to warfarin was evident, this was irrespective of renal function changes over time. In patients with normal renal function, dabigatran 110 mg resulted in relatively greater risk reduction of major bleeding events during follow-up.